Allocation: {concealed}*.
Blinding: blinded {patients, clinicians, and data monitoring committee}*.
Follow up period: 5 years.
Setting: {69 hospitals in the UK}*.
Patients: 20 536 patients (mean age 64 y, 75% men) who had non-fasting blood total cholesterol concentrations >3.5 mmol/l (135 mg/dl) and a medical history of cerebrovascular disease, coronary disease, other occlusive arterial disease, diabetes, or were men >65 years with treated hypertension. Exclusion criteria: clear indication or non-indication for statin therapy; stroke, myocardial infarction, or admission for angina in the previous 6 months; chronic liver disease; severe renal disease; inflammatory muscle disease; concurrent treatment with ciclosporin, fibrates, or high dose niacin; child bearing potential; severe heart failure; or life threatening conditions. Intervention: simvastatin, 40 mg daily (n = 10 269) or matching placebo (n = 10 267) for 5 years.
Outcomes: first major vascular events (ie, non-fatal myocardial infarction or coronary death, stroke, or revascularisation procedure). Secondary outcomes included total (non-fatal and fatal) stroke, presumed ischaemic stroke, and haemorrhagic stroke.
Patient follow up: {99.7% of patients had complete follow up over 5 years}* (intention to treat analysis).
*Heart Protection Study Collaborative Group. Lancet 2002; 360:7-22.
MAIN RESULTS
At 5 years, patients in the simvastatin group had greater reductions in first occurrence of major vascular events and stroke than patients in the placebo group (table). The groups did not differ for haemorrhagic stroke (0.5% v 0.5%).
CONCLUSION
Cholesterol lowering with simvastatin reduced stroke in patients with, or at high risk of, vascular disease. *Abbreviations defined in glossary; NNT and CI calculated from control event rate and rate ratio reported in article. ÀNon-fatal myocardial infarction or coronary death, stroke, or revascularisation procedure.
